Damian Garde

Biography for Damian Garde

Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at dgarde@fiercemarkets.com and follow @DamianFierce on Twitter.

Articles by Damian Garde

Vital Therapies banks $54M in a downsized IPO retry

After pulling the plug on an $86 million float in biotech's halcyon 2013, Vital Therapies has made its way to Wall Street with a scaled-down $54 million offering, cash it will use to advance its drug-device combo for liver failure.

GlaxoSmithKline and Galapagos succeed in psoriasis after two setbacks

Galapagos and partner GlaxoSmithKline say their anti-inflammation candidate hit its mark in a mid-stage trial on psoriasis, a stroke of good news for a drug beset by developmental slipups.

Baxter's latest bleeding drug hits the mark in PhIII

Baxter charted another late-stage success in its growing hemophilia franchise, posting positive top-line results for an orphan bleeding disorder treatment.

BioAlliance and Topotarget plan to merge, pooling their cancer pipelines

European biotechs BioAlliance Pharma and Topotarget have signed up to join forces, plotting to merge under the former's name and combine their pipelines of late-stage oncology drugs.

GlaxoSmithKline wins an FDA nod for its GLP-1 diabetes drug albiglutide

After a three-month delay pushed pause on its commercial plans, GlaxoSmithKline has secured FDA approval for albiglutide, a new diabetes treatment that will contend for market share in a fast-crowding space.

Angion swings for a $36M IPO as biotech's bear turn drags on

Uniondale, NY's Angion Biomedica is eyeing $36 million to bankroll its pipeline of treatments for organ injury, hoping to buck an alarming trend for biotech stocks and trade on the Nasdaq under "ANGN."

Startup AAVLife sets sights on ataxia with $12M and a novel gene therapy

Parisian biotech AAVLife has come out of stealth with a Versant Ventures-led $12 million A round, looking to advance a gene-deleting therapy that promises to treat the rare and deadly Friedreich's ataxia.

Merck bags FDA approval for its grass pollen pill Grastek

Merck picked up an expected FDA approval for the first of three immunotherapies in its allergy pipeline, gearing up to launch a grass pollen-fighting treatment with hopes of cracking a market dominated by injections.

ThromboGenics is picking between billion-dollar bids, report says

Just over a month into its search for "strategic options," ThromboGenics has rounded up a bevy of high-dollar offers that could value the company at as much as $1.3 billion, Bloomberg reports, courted by drugmakers who see promise in its underperforming eye drug.

Biotech stocks tumble on phantom terror as analysts struggle to explain

The Nasdaq biotech index slumped another 5.6% on Thursday, and it's apparently anyone's guess as to why.